EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer

BACKGROUND: As supplement to KRAS mutational analysis, BRAF and PIK3CA mutations as well as expression of PTEN may account for additional non-responders to anti-EGFR-MoAbs treatment. The aim of the present study was to investigate the utility as biomarkers of these mutations in a uniform cohort of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Spindler, Karen-Lise G, Pallisgaard, Niels, Lindebjerg, Jan, Frifeldt, Sanne K, Jakobsen, Anders
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073939/
https://www.ncbi.nlm.nih.gov/pubmed/21439039
http://dx.doi.org/10.1186/1471-2407-11-107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073939/
https://www.ncbi.nlm.nih.gov/pubmed/21439039
http://dx.doi.org/10.1186/1471-2407-11-107

Ejemplares similares